Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate

M. S. Soloway, R. M. Shippel, M. Ikard

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy. All patients had extensive bone metastases. Of the 21 patients 5 (29 per cent) had a subjective response and an additional 12 (57 per cent) remained stable for 2 to 13 months after initiation of therapy. The median survival of patients with a subjective response was 60 weeks compared to 40 weeks for the stable patients. Patients who progressed on therapy had a median survival of 22 weeks. The significant response rate with a corresponding improvement in survival for patients on this 3-drug regimen suggests a need for additional trials to determine the response rate and survival compared to single agents.

Original languageEnglish
Pages (from-to)637-639
Number of pages3
JournalJournal of Urology
Volume122
Issue number5
StatePublished - Dec 1 1979
Externally publishedYes

Fingerprint

Fluorouracil
Doxorubicin
Cyclophosphamide
Prostate
Carcinoma
Survival
Combination Drug Therapy
Adenocarcinoma
Therapeutics
Survival Rate
Neoplasm Metastasis
Bone and Bones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. / Soloway, M. S.; Shippel, R. M.; Ikard, M.

In: Journal of Urology, Vol. 122, No. 5, 01.12.1979, p. 637-639.

Research output: Contribution to journalArticle

Soloway, M. S. ; Shippel, R. M. ; Ikard, M. / Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. In: Journal of Urology. 1979 ; Vol. 122, No. 5. pp. 637-639.
@article{e49cc923bb9540609e48f0fb832875ac,
title = "Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate",
abstract = "Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy. All patients had extensive bone metastases. Of the 21 patients 5 (29 per cent) had a subjective response and an additional 12 (57 per cent) remained stable for 2 to 13 months after initiation of therapy. The median survival of patients with a subjective response was 60 weeks compared to 40 weeks for the stable patients. Patients who progressed on therapy had a median survival of 22 weeks. The significant response rate with a corresponding improvement in survival for patients on this 3-drug regimen suggests a need for additional trials to determine the response rate and survival compared to single agents.",
author = "Soloway, {M. S.} and Shippel, {R. M.} and M. Ikard",
year = "1979",
month = "12",
day = "1",
language = "English",
volume = "122",
pages = "637--639",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate

AU - Soloway, M. S.

AU - Shippel, R. M.

AU - Ikard, M.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy. All patients had extensive bone metastases. Of the 21 patients 5 (29 per cent) had a subjective response and an additional 12 (57 per cent) remained stable for 2 to 13 months after initiation of therapy. The median survival of patients with a subjective response was 60 weeks compared to 40 weeks for the stable patients. Patients who progressed on therapy had a median survival of 22 weeks. The significant response rate with a corresponding improvement in survival for patients on this 3-drug regimen suggests a need for additional trials to determine the response rate and survival compared to single agents.

AB - Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy. All patients had extensive bone metastases. Of the 21 patients 5 (29 per cent) had a subjective response and an additional 12 (57 per cent) remained stable for 2 to 13 months after initiation of therapy. The median survival of patients with a subjective response was 60 weeks compared to 40 weeks for the stable patients. Patients who progressed on therapy had a median survival of 22 weeks. The significant response rate with a corresponding improvement in survival for patients on this 3-drug regimen suggests a need for additional trials to determine the response rate and survival compared to single agents.

UR - http://www.scopus.com/inward/record.url?scp=0018577627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018577627&partnerID=8YFLogxK

M3 - Article

C2 - 501816

AN - SCOPUS:0018577627

VL - 122

SP - 637

EP - 639

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -